{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T20:09:41Z","timestamp":1778962181673,"version":"3.51.4"},"reference-count":39,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,1,22]],"date-time":"2025-01-22T00:00:00Z","timestamp":1737504000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100005564","name":"Gilead Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005564","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Enfermedades infecciosas y microbiologia clinica (English ed.)"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1016\/j.eimce.2024.12.003","type":"journal-article","created":{"date-parts":[[2024,12,30]],"date-time":"2024-12-30T07:32:40Z","timestamp":1735543960000},"page":"251-259","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Cost analysis associated with intramuscular versus oral administration of antiretroviral therapy in the management of human immunodeficiency virus infection"],"prefix":"10.1016","volume":"43","author":[{"given":"Vicente","family":"Estrada","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juan Emilio","family":"Losa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ram\u00f3n","family":"Morillo-Verdugo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Montserrat","family":"P\u00e9rez-Encinas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jes\u00fas","family":"Santos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonio","family":"Castro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5925-0619","authenticated-orcid":false,"given":"Mar\u00eda","family":"Presa Gonz\u00e1lez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7066-0659","authenticated-orcid":false,"given":"Laura","family":"Salinas-Ortega","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.eimce.2024.12.003_bib0005","unstructured":"Centro Nacional de Epidemiolog\u00eda \u2013 Instituto de Salud Carlos III\/ Divisi\u00f3n de control de VIH, ITS, Hepatitis Virales y Tuberculosis \u2013 Direcci\u00f3n General de Salud P\u00fablica. Unidad de vigilancia de VIH, ITS y hepatitis. Actualizaci\u00f3n del continuo de atenci\u00f3n del VIH en Espa\u00f1a 2021-2022, https:\/\/www.isciii.es\/QueHacemos\/Servicios\/VigilanciaSaludPublicaRENAVE\/EnfermedadesTransmisibles\/Documents\/VIH\/INFORMES%20ESPECIALES\/ESTIMACION%20DEL%20CONTINUO%20DE%20ATENCI\u00d3N%20DEL%20VIH%20EN%20ESPA\u00d1A_Mayo%202023.pdf; 2023 [acceso 4 diciembre 2023]."},{"key":"10.1016\/j.eimce.2024.12.003_bib0010","unstructured":"AEMPS, Ministerio Informe de Posicionamiento Terap\u00e9utico de la combinaci\u00f3n de cabotegravir (Vocabria\u00ae) y rilpivirina (Rekambys\u00ae) inyectables en la infecci\u00f3n por VIH, https:\/\/www.aemps.gob.es\/medicamentosUsoHumano\/informesPublicos\/docs\/2023\/IPT-086-2023-Vocabria.pdf; [acceso 4 diciembre 2023]."},{"key":"10.1016\/j.eimce.2024.12.003_bib0015","unstructured":"Sociedad Espa\u00f1ola de Farmacia Hospitalaria (SEFH). Gu\u00eda Pr\u00e1ctica de Atenci\u00f3n Farmac\u00e9utica Multidisciplinar y Multidimensional: Paciente con infecci\u00f3n por VIH en tratamiento con f\u00e1rmacos long-acting, https:\/\/www.sefh.es\/bibliotecavirtual\/sefh_vih\/guiapract_VIH.pdf?ts=20230427073304; 2022 [acceso 4 diciembre 2023]."},{"key":"10.1016\/j.eimce.2024.12.003_bib0020","unstructured":"GESIDA, Plan Nacional sobre el Sida. Documento de consenso de GeSIDA\/Plan Nacional sobre el Sida respecto al tratamiento antirretroviral en adultos infectados por el virus de la inmunodeficiencia humana (Actualizaci\u00f3n enero 2023), https:\/\/gesida-seimc.org\/wp-content\/uploads\/2023\/02\/Guia_Modificada_DocumentoDeConsensoDeGeSIDAPlanNacionalSobreElSidaRespectoAlTratamientoAntirretroviralEnAdultosInfectadosPorElVirusDeLaInmunodeficienciaHumana.pdf; 2023 [acceso 4 Diciembre 2023]."},{"issue":"8","key":"10.1016\/j.eimce.2024.12.003_bib0025","doi-asserted-by":"crossref","first-page":"e349","DOI":"10.1016\/S2352-3018(17)30066-8","article-title":"Survival of HIV-positive patients starting antiretroviral therapy between 1996 and 2013: a collaborative analysis of cohort studies","volume":"4","author":"Trickey","year":"2017","journal-title":"The Lancet HIV"},{"issue":"8","key":"10.1016\/j.eimce.2024.12.003_bib0030","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.1007\/s40121-023-00840-y","article-title":"Cabotegravir and rilpivirine long-acting antiretroviral therapy administered every 2 months is cost-effective for the treatment of HIV-1 in Spain","volume":"12","author":"Moreno","year":"2023","journal-title":"Infect Dis Ther."},{"issue":"10267","key":"10.1016\/j.eimce.2024.12.003_bib0035","doi-asserted-by":"crossref","first-page":"1994","DOI":"10.1016\/S0140-6736(20)32666-0","article-title":"Long-acting cabotegravir and rilpivirine dosed every 2 months in adults with HIV-1 infection (ATLAS-2M), 48-week results: a randomised, multicentre, open-label, phase 3b, non-inferiority study","volume":"396","author":"Overton","year":"2021","journal-title":"Lancet."},{"issue":"32","key":"10.1016\/j.eimce.2024.12.003_bib0040","article-title":"Impact of HIV-related stigma on treatment adherence: systematic review and meta-synthesis","volume":"16","author":"Katz","year":"2013","journal-title":"J Int AIDS Soc"},{"key":"10.1016\/j.eimce.2024.12.003_bib0045","doi-asserted-by":"crossref","first-page":"831","DOI":"10.3389\/fphar.2017.00831","article-title":"Improving the Adherence to Antiretroviral Therapy, a Difficult but Essential Task for a Successful HIV Treatment\u2014Clinical Points of View and Practical Considerations","volume":"8","author":"Iacob","year":"2017","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.eimce.2024.12.003_bib0050","unstructured":"Agencia Espa\u00f1ola de Medicamentos y Productos Sanitarios (AEMPS). Ficha t\u00e9cnica Rekambys en suspensi\u00f3n inyectable de liberaci\u00f3n prolongada, https:\/\/cima.aemps.es\/cima\/pdfs\/es\/p\/1201482002\/P_1201482002.pdf; 2020 [acceso 4 diciembre 2023]."},{"key":"10.1016\/j.eimce.2024.12.003_bib0055","unstructured":"Agencia Espa\u00f1ola de Medicamentos y Productos Sanitarios (AEMPS). Ficha t\u00e9cnica Vocabria en suspensi\u00f3n inyectable de liberaci\u00f3n prolongada, https:\/\/cima.aemps.es\/cima\/dochtml\/ft\/1201481003\/FT_1201481003.html; 2020 [acceso 4 diciembre 2023]."},{"key":"10.1016\/j.eimce.2024.12.003_bib0060","unstructured":"Ministerio de Agricultura, Pesca y Alimentaci\u00f3n. An\u00e1lisis y Prospectiva: Demograf\u00eda de la poblaci\u00f3n rural en 2020, https:\/\/www.mapa.gob.es\/es\/ministerio\/servicios\/analisis-y-prospectiva\/ayp_demografiaenlapoblacionrural2020_tcm30-583987.pdf; 2021 [acceso 4 diciembre 2023]."},{"key":"10.1016\/j.eimce.2024.12.003_bib0065","series-title":"Distribuci\u00f3n de la poblaci\u00f3n y accesibilidad a los servicios en Espa\u00f1a [Internet]","first-page":"160","author":"Goerlich","year":"2021"},{"key":"10.1016\/j.eimce.2024.12.003_bib0070","unstructured":"Ministerio de transportes, movilidad y agenda urbana. Observatorio del Transporte y la Log\u00edstica en Espa\u00f1a (OTLE). Informe anual OTLE del transporte y la Log\u00edstica en Espa\u00f1a, https:\/\/cdn.mitma.gob.es\/portal-web-drupal\/OTLE\/elementos_otle\/Informe_anual_2022%20(febrero_2023).pdf; 2022 [acceso 4 diciembre 2023]."},{"key":"10.1016\/j.eimce.2024.12.003_bib0075","unstructured":"Ministerio para la Transici\u00f3n Ecol\u00f3gica y el Reto Demogr\u00e1fico. Precios de carburantes y combustibles. Datos de marzo de 2023, https:\/\/energia.gob.es\/petroleo\/Informes\/InformesMensuales\/DatosBibliotecaConsumer\/2023\/Marzo%202023.pdf; 2023 [acceso 4 diciembre 2023]."},{"key":"10.1016\/j.eimce.2024.12.003_bib0080","unstructured":"Precios de transportes y servicios en Espa\u00f1a 2023, https:\/\/preciosmundi.com\/espana\/precio-transporte-servicios; 2023 [acceso 4 diciembre 2023]."},{"key":"10.1016\/j.eimce.2024.12.003_bib0085","series-title":"En: Ministerio de sanidad, consumo y bienestar social","first-page":"30","article-title":"Situaci\u00f3n laboral de las personas con infecci\u00f3n por el VIH en Espa\u00f1a","author":"Rodr\u00edguez Ortiz de Salazar","year":"2018"},{"issue":"3","key":"10.1016\/j.eimce.2024.12.003_bib0090","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.eimc.2018.04.010","article-title":"Analysis of the costs and cost-effectiveness of the guidelines recommended by the 2018 GESIDA\/Spanish National AIDS Plan for initial antiretroviral therapy in HIV-infected adults","volume":"37","author":"P\u00e9rez-Molina","year":"2019","journal-title":"Enferm Infecc Microbiol Clin (Engl Ed)"},{"key":"10.1016\/j.eimce.2024.12.003_bib0095","series-title":"Base de datos de costes sanitarios y ratios coste-efectividad espa\u00f1oles: eSalud","author":"Gisbert","year":"2007"},{"key":"10.1016\/j.eimce.2024.12.003_bib0100","unstructured":"Instituto Nacional de Estad\u00edstica (INE). C\u00e1lculo de variaciones del Indice de Precios de Consumo [Internet]. INE. Available from: https:\/\/www.ine.es\/varipc\/index.do [acceso 4 diciembre 2023]."},{"issue":"11","key":"10.1016\/j.eimce.2024.12.003_bib0105","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/S0025-7753(04)74260-8","article-title":"An\u00e1lisis de costes y resultados en la evaluaci\u00f3n econ\u00f3mica de las intervenciones sanitarias","volume":"122","author":"Prieto","year":"2004","journal-title":"Med Clin (Barc) [Internet]"},{"issue":"1","key":"10.1016\/j.eimce.2024.12.003_bib0110","doi-asserted-by":"crossref","first-page":"5","DOI":"10.4321\/S1135-57272015000100002","article-title":"Cuestiones controvertidas en evaluaci\u00f3n econ\u00f3mica (I): perspectiva y costes de intervenciones sanitarias","volume":"89","author":"Oliva","year":"2015","journal-title":"Revista Espa\u00f1ola de Salud P\u00fablica [Internet]"},{"key":"10.1016\/j.eimce.2024.12.003_bib0115","unstructured":"Centro Nacional de Epidemiolog\u00eda. Instituto de Salud Carlos III\/ Divisi\u00f3n de control de VIH, ITS, Hepatitis virales y tuberculosis. Unidad de vigilancia de VIH, ITS y hepatitis. Vigilancia Epidemiol\u00f3gica del VIH y sida en Espa\u00f1a 2021: Sistema de informaci\u00f3n sobre Nuevos Diagn\u00f3sticos de VIH y Registro Nacional de Sida, https:\/\/www.isciii.es\/QueHacemos\/Servicios\/VigilanciaSaludPublicaRENAVE\/EnfermedadesTransmisibles\/Documents\/VIH\/informes%20de%20vigilancia%20VIH%20y%20sida%20anteriores\/Informe%20VIH_SIDA_2022_CCAA.pdf; 2022 [acceso 4 diciembre 2023]."},{"key":"10.1016\/j.eimce.2024.12.003_bib0120","unstructured":"Pharmacoeconomic Review Report: Cabotegravir Tablets, Cabotegravir Extended-Release Injectable Suspension, and Rilpivirine Extended-Release Injectable Suspension (Vocabria, Cabenuva): (ViiV Healthcare ULC): Indication: HIV-1 infection [Internet]. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2020. (CADTH Common Drug Reviews). Available from: http:\/\/www.ncbi.nlm.nih.gov\/books\/NBK566628\/."},{"key":"10.1016\/j.eimce.2024.12.003_bib0125","doi-asserted-by":"crossref","first-page":"3621","DOI":"10.2147\/JMDH.S343528","article-title":"Outpatients\u2019 opinion and experience regarding telepharmacy during the COVID-19 pandemic: the Enopex project","volume":"14","author":"Margusino-Frami\u00f1\u00e1n","year":"2021","journal-title":"J Multidiscip Healthc [Internet]"},{"issue":"3","key":"10.1016\/j.eimce.2024.12.003_bib0130","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.eimc.2021.07.013","article-title":"Healthcare outcomes in patients with HIV infection at a tertiary hospital during the COVID-19 pandemic","volume":"41","author":"Quir\u00f3s-Gonz\u00e1lez","year":"2023","journal-title":"Enferm Infecc Microbiol Clin."},{"key":"10.1016\/j.eimce.2024.12.003_bib0135","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.2147\/JMDH.S406636","article-title":"Evaluation of patient experience with a model of coordinated telematic pharmaceutical care between hospital and rural pharmacies in spain: a proof of concept","volume":"16","author":"Morillo-Verdugo","year":"2023","journal-title":"J Multidiscip Healthc"},{"issue":"4","key":"10.1016\/j.eimce.2024.12.003_bib0140","first-page":"135","article-title":"Survey on the situation of telepharmacy as applied to the outpatient care in hospital pharmacy departments in Spain during the COVID-19 pandemic","volume":"44","author":"Tortajada-Goitia","year":"2020","journal-title":"Farm Hosp."},{"issue":"7","key":"10.1016\/j.eimce.2024.12.003_bib0145","first-page":"69","article-title":"Outpatient pharmaceutical care satisfaction survey through Telepharmacy during COVID-19 pandemic in Spain","volume":"46","author":"Mercadal-Orfila","year":"2022","journal-title":"Farm Hosp."},{"key":"10.1016\/j.eimce.2024.12.003_bib0150","series-title":"Long-Acting CAB + RPV Fails With Resistance in 5 After Long Control on Oral Regimens","author":"Mascolini","year":"2023"},{"key":"10.1016\/j.eimce.2024.12.003_bib0155","series-title":"Failure following switch from long-term suppressive oral ART to long-acting cabotegravir plus rilpivirine","author":"van Welsen","year":"2023"},{"key":"10.1016\/j.eimce.2024.12.003_bib0160","series-title":"Effectiveness of LA Injectable Cabotegravir+Rilpivirine for the Treatment of HIV-1: results from the Dutch Athena national observation cohort","author":"Jongen","year":"2023"},{"key":"10.1016\/j.eimce.2024.12.003_bib0165","series-title":"Dise\u00f1o e implantaci\u00f3n de un circuito de atenci\u00f3n farmac\u00e9utica integral en pacientes VIH en tratamiento long acting","author":"del Estal Jim\u00e9nez","year":"2023"},{"key":"10.1016\/j.eimce.2024.12.003_bib0170","series-title":"Implantaci\u00f3n del circuito de prescipci\u00f3n, validaci\u00f3n, dispensaci\u00f3n y administraci\u00f3n de cabotegravir y rilpivirina","author":"Espadas Herv\u00e1s","year":"2023"},{"key":"10.1016\/j.eimce.2024.12.003_bib0175","series-title":"Implementaci\u00f3n de un circuito para la prescipci\u00f3n, validaci\u00f3n, dispensaci\u00f3n y administraci\u00f3n hospitalaria del cabotegravir\/rilpivirina intramuscular","author":"D\u00edaz-Calder\u00f3n Horcada","year":"2023"},{"key":"10.1016\/j.eimce.2024.12.003_bib0180","series-title":"Implementaci\u00f3n del circuito de cabotegravir+rilpivirina intramuscular en el hospital","author":"Codonal Demetrio","year":"2023"},{"issue":"2","key":"10.1016\/j.eimce.2024.12.003_bib0185","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0245955","article-title":"Cost-effectiveness of the long-acting regimen cabotegravir plus rilpivirine for the treatment of HIV-1 and its potential impact on adherence and viral transmission: a modelling study","volume":"16","author":"Parker","year":"2021","journal-title":"PLoS One"},{"issue":"6","key":"10.1016\/j.eimce.2024.12.003_bib0190","first-page":"327","article-title":"Analysis of the costs associated with the follow-up of HIV patients discontinuing antiretroviral treatment due to lack of effectiveness or unacceptable toxicity in Spain","volume":"46","author":"Castro","year":"2022","journal-title":"Farm Hosp."},{"key":"10.1016\/j.eimce.2024.12.003_bib0195","unstructured":"INE. Salario anual medio, mediano y modal. Salario por hora. Brecha salarial de g\u00e9nero (no ajustada) en salarios por hora, https:\/\/www.ine.es\/ss\/Satellite?L=es_ES&c=INESeccion_C&cid=1259925408327&p=%5C&pagename=ProductosYServicios%2FPYSLayout; 2023 [acceso 4 diciembre 2023]."}],"container-title":["Enfermedades infecciosas y microbiologia clinica (English ed.)"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2529993X24002582?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2529993X24002582?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T19:50:34Z","timestamp":1778961034000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2529993X24002582"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5]]},"references-count":39,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,5]]}},"alternative-id":["S2529993X24002582"],"URL":"https:\/\/doi.org\/10.1016\/j.eimce.2024.12.003","relation":{},"ISSN":["2529-993X"],"issn-type":[{"value":"2529-993X","type":"print"}],"subject":[],"published":{"date-parts":[[2025,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cost analysis associated with intramuscular versus oral administration of antiretroviral therapy in the management of human immunodeficiency virus infection","name":"articletitle","label":"Article Title"},{"value":"Enfermedades infecciosas y microbiologia clinica (English ed.)","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eimce.2024.12.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.eimc.2024.07.013","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Espa\u00f1a, S.L.U. on behalf of Sociedad Espa\u00f1ola de Enfermedades Infecciosas y Microbiolog\u00eda Cl\u00ednica.","name":"copyright","label":"Copyright"}]}}